Latest Breaking News On - Agios pharmaceuticals - Page 1 : comparemela.com

Agios Pharmaceuticals (NASDAQ:AGIO) Rating Increased to Hold at StockNews.com

StockNews.com upgraded shares of Agios Pharmaceuticals (NASDAQ:AGIO – Free Report) from a sell rating to a hold rating in a research note issued to investors on Wednesday. Several other analysts also recently weighed in on AGIO. Royal Bank of Canada reduced their target price on Agios Pharmaceuticals from $43.00 to $42.00 and set an outperform […]

Leerink Partnrs Comments on Agios Pharmaceuticals, Inc.'s Q4 2024 Earnings (NASDAQ:AGIO)

Royalty Pharma : Vorasidenib Transaction Call Transcript

REFINITIV STREETEVENTS EDITED TRANSCRIPT RPRX.OQ - Royalty Pharma PLC To Host Investor Call .

Agios sells vorasidenib royalty rights to Royalty Pharma for $905M

Vorasidenib, which treats IDH-mutant diffuse glioma, showed efficacy in data released last year.

Agios Stock Poised To Break Out On $905 Million Brain Cancer Deal

Agios agreed Tuesday to sell its 15% royalty in a brain cancer drug for $905 million upfront. Agios stock broke out at the open.